Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Hold" by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) have received an average rating of "Hold" from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.29.

A number of analysts have weighed in on the stock. Barclays restated an "equal weight" rating and set a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. William Blair restated a "market perform" rating on shares of Revance Therapeutics in a report on Monday, August 12th. Piper Sandler downgraded Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 12th. StockNews.com started coverage on Revance Therapeutics in a research note on Thursday. They issued a "hold" rating for the company. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Revance Therapeutics in a report on Monday, August 12th.

Institutional Trading of Revance Therapeutics

A number of hedge funds have recently bought and sold shares of RVNC. Capital World Investors increased its position in shares of Revance Therapeutics by 16.8% during the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company's stock valued at $68,612,000 after purchasing an additional 2,006,459 shares during the last quarter. Vanguard Group Inc. grew its position in Revance Therapeutics by 6.5% during the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company's stock valued at $26,560,000 after buying an additional 328,781 shares during the period. Stonepine Capital Management LLC increased its holdings in Revance Therapeutics by 41.7% during the second quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company's stock valued at $7,196,000 after buying an additional 823,658 shares during the last quarter. Federated Hermes Inc. raised its position in Revance Therapeutics by 43.0% in the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company's stock worth $5,750,000 after acquiring an additional 672,803 shares during the period. Finally, Opaleye Management Inc. purchased a new position in shares of Revance Therapeutics during the 1st quarter worth $3,862,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Revance Therapeutics Price Performance

RVNC stock traded up $0.11 on Friday, reaching $5.29. 1,887,082 shares of the company traded hands, compared to its average volume of 2,770,215. Revance Therapeutics has a one year low of $2.30 and a one year high of $9.74. The company has a market cap of $554.50 million, a P/E ratio of -1.66 and a beta of 0.98. The firm has a fifty day simple moving average of $5.99 and a 200-day simple moving average of $4.28.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The company had revenue of $65.39 million during the quarter, compared to analysts' expectations of $66.30 million. The company's revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.80) earnings per share. On average, sell-side analysts forecast that Revance Therapeutics will post -1.53 EPS for the current year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.